Axonics® provides additional update on inter partes review proceedings

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the patent trial and appeal board (ptab) of the u.s. patent and trademark office has issued final written decisions on three additional medtronic patents that axonics is contesting. in march 2020, axonics filed petitions with the ptab requesting inter partes review (ipr) t
AXNX Ratings Summary
AXNX Quant Ranking